Sirexatamab
Uterine Cancer
Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Leap Therapeutics, Inc.
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
42High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03395080CT.gov A Study of DKN-01 as a Monotherapy or in Combination With Paclitaxel in Patients With Recurrent Epithelial Endometrial or Epithelial Ovarian Cancer or Carcinosarcoma | — | Completed | — | — | — |
NCT04681248CT.gov Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Uterine Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sirexatamab (this asset) | Leap Therapeutics, Inc. | P2 | B · 57 |
| GALFER | Sunnybrook Health Sciences Centre | P4 | BB |
| Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- | Gynecologic Oncology Associates | P4 | BB |
| Nivolumab | National Cancer Institute (NCI) | P2 | B |
| Marcaine | University of California, Irvine | P3 | B |
| Durvalumab | Mary Crowley Medical Research Center | P2 | B |
| Gemogenovatucel-T | Gradalis, Inc. | P2 | B |
| Atezolizumab | Gradalis, Inc. | P2 | B |
| Cabozantinib | National Cancer Institute (NCI) | P2 | B |
+42 more in the Uterine Cancer cohort
Other indications for Sirexatamab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Carcinosarcoma | — | P2 | B · 57 |
| Colorectal Adenocarcinoma | — | P2 | CCC · 54 |
| Metastatic Malignant Neoplasm In The Colon | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Sirexatamab in Uterine Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/sirexatamab-uterine-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →